Celgene Diversifying Beyond Myeloma Backbone Revlimid

Promising pipeline will continue to deliver as Revlimid matures.

Celgene Corp.'s product sales increased 21% and earnings grew 27% in 2015, as expected based on guidance given earlier in January, but the company is poised for revenue gains beyond its multiple myeloma backbone therapy Revlimid (lenalidomide) as new product sales growth continues.

Revlimid will remain the largest income producer in Celgene's portfolio for the foreseeable future, but executives highlighted sales gains for...